NO985337L - Tetrahydrolipstatin-holdige blandinger - Google Patents

Tetrahydrolipstatin-holdige blandinger

Info

Publication number
NO985337L
NO985337L NO985337A NO985337A NO985337L NO 985337 L NO985337 L NO 985337L NO 985337 A NO985337 A NO 985337A NO 985337 A NO985337 A NO 985337A NO 985337 L NO985337 L NO 985337L
Authority
NO
Norway
Prior art keywords
tetrahydrolipstatin
containing mixtures
mixtures
Prior art date
Application number
NO985337A
Other languages
English (en)
Other versions
NO985337D0 (no
NO320445B1 (no
Inventor
Navnit Hargovindas Shah
Max Zeller
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26671373&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO985337(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of NO985337L publication Critical patent/NO985337L/no
Publication of NO985337D0 publication Critical patent/NO985337D0/no
Publication of NO320445B1 publication Critical patent/NO320445B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NO19985337A 1997-02-05 1998-11-16 Tetrahydrolipstatinholdige farmasoytiske blandinger NO320445B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3738497P 1997-02-05 1997-02-05
US09/003,137 US6004996A (en) 1997-02-05 1998-01-06 Tetrahydrolipstatin containing compositions
PCT/EP1998/000395 WO1998034607A1 (en) 1997-02-05 1998-01-24 Tetrahydrolipstatin containing compositions

Publications (3)

Publication Number Publication Date
NO985337L true NO985337L (no) 1998-11-16
NO985337D0 NO985337D0 (no) 1998-11-16
NO320445B1 NO320445B1 (no) 2005-12-05

Family

ID=26671373

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19985337A NO320445B1 (no) 1997-02-05 1998-11-16 Tetrahydrolipstatinholdige farmasoytiske blandinger

Country Status (29)

Country Link
US (1) US6004996A (no)
EP (1) EP0921796B1 (no)
CN (1) CN1193752C (no)
AR (1) AR010704A1 (no)
AT (1) ATE200027T1 (no)
AU (1) AU713192B2 (no)
CA (1) CA2258095C (no)
CO (1) CO4920214A1 (no)
CY (1) CY2264B1 (no)
CZ (1) CZ287154B6 (no)
DE (1) DE69800639T2 (no)
DK (1) DK0921796T3 (no)
ES (1) ES2156028T3 (no)
GR (1) GR3036064T3 (no)
HR (1) HRP980057B1 (no)
HU (1) HU225035B1 (no)
ID (1) ID26509A (no)
IL (1) IL126902A (no)
MA (1) MA24466A1 (no)
MY (1) MY118371A (no)
NO (1) NO320445B1 (no)
NZ (1) NZ332659A (no)
PE (1) PE57599A1 (no)
PT (1) PT921796E (no)
RU (1) RU2170579C2 (no)
SI (1) SI0921796T1 (no)
UY (1) UY24875A1 (no)
WO (1) WO1998034607A1 (no)
YU (1) YU49423B (no)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL191222B1 (pl) * 1997-02-05 2006-03-31 Hoffmann La Roche Zastosowanie tetrahydrolipstatyny do wytwarzania doustnego farmaceutycznego preparatu do leczenia cukrzycy typu II
CA2340056C (en) 1998-08-14 2007-01-09 F. Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors
AU745697B2 (en) * 1998-09-08 2002-03-28 Smithkline Beecham Corporation Lipstatin derivative-soluble fiber tablets
AR025609A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
AR025587A1 (es) * 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
EP1132389A1 (en) 2000-03-06 2001-09-12 Vernalis Research Limited New aza-indolyl derivatives for the treatment of obesity
DE10021618A1 (de) * 2000-05-04 2001-11-15 Volker Helmstaedter Präparat für Darmerkrankungen und dessen Verwendung
ES2269441T3 (es) * 2000-06-27 2007-04-01 F. Hoffmann-La Roche Ag Metodo para la preparacion de una composicion.
KR100572785B1 (ko) * 2000-07-28 2006-04-19 에프. 호프만-라 로슈 아게 신규한 약학 조성물
ATE293477T1 (de) 2000-07-28 2005-05-15 Hoffmann La Roche Neue verwendung von lipase-inhibitoren
CA2417607C (en) 2000-08-09 2008-01-29 Christine Feinle Lipase inhibitors for the treatment of dyspepsia
US6900226B2 (en) * 2000-09-06 2005-05-31 Hoffman-La Roche Inc. Neuropeptide Y antagonists
WO2002044152A1 (en) 2000-10-16 2002-06-06 F. Hoffmann-La Roche Ag Indoline derivatives and their use as 5-ht2 receptor ligands
GB0030710D0 (en) * 2000-12-15 2001-01-31 Hoffmann La Roche Piperazine derivatives
BR0116605A (pt) 2000-12-27 2003-09-30 Hoffmann La Roche Composto, processo para a preparação de um composto, composição farmacêutica que compreende o mesmo, sua utilização e processo para o tratamento e profilaxia de distúrbios do sistema nervoso central, distúrbios cardiovasculares, distúrbios gastrintestinais e apnéia do sono
GB0106177D0 (en) * 2001-03-13 2001-05-02 Hoffmann La Roche Piperazine derivatives
AU2002338896B2 (en) * 2001-05-21 2006-04-27 F.Hoffman-La Roche Ag Quinoline derivatives as ligands for the neuropeptide Y receptor
US20030027786A1 (en) * 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US6787558B2 (en) * 2001-09-28 2004-09-07 Hoffmann-La Roche Inc. Quinoline derivatives
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
DE10152351B4 (de) * 2001-10-18 2005-09-22 Schering Ag Feste Arzneimittelformulierung für ein Piperazinharnstoffderivat
WO2003039516A1 (en) * 2001-11-07 2003-05-15 Fujisawa Pharmaceuticla Co., Ltd. Method for improving dissolution of poorly dispersible medicaments
ATE333270T1 (de) * 2001-12-20 2006-08-15 Alpex Pharma Sa Pharmazeutische zusammensetzung enthaltend magermilchpulver
GB0202015D0 (en) * 2002-01-29 2002-03-13 Hoffmann La Roche Piperazine Derivatives
PL372295A1 (en) * 2002-02-04 2005-07-11 F.Hoffmann-La Roche Ag Quinoline derivatives as npy antagonists
BR0308108A (pt) 2002-02-28 2004-12-07 Hoffmann La Roche Compostos; processo para a preparação de composto; composição farmacêutica que compreende o mesmo, utilização dos compostos e método de tratamento e profilaxia de enfermidades e de obesidade
PL216022B1 (pl) * 2002-04-26 2014-02-28 Hoffmann La Roche Kompozycja farmaceutyczna, sposób jej wytwarzania i jej zastosowanie, zestaw do leczenia otylosci, inhibitor lipazy w postaci orlistatu i glukomannan lub konjac, zastosowanie inhibitora lipazy w postaci orlistatu oraz zastosowanie glukomannanu lub konjacu
CA2489251A1 (en) * 2002-07-05 2004-01-15 F. Hoffmann-La Roche Ag Quinazoline derivatives
AU2003253364B2 (en) * 2002-08-07 2007-06-07 F. Hoffmann-La Roche Ag Thiazole derivatives
WO2004024726A1 (en) * 2002-09-12 2004-03-25 F. Hoffmann-La Roche Ag N-substituted-1h-indol-5-propionic acid compounds as ppar agonists useful for the treatment of diabetes
DE60323130D1 (de) * 2002-11-25 2008-10-02 Hoffmann La Roche Indolderivaten
US20040178058A1 (en) * 2003-03-10 2004-09-16 Hsueh-Chung Chen Electro-chemical deposition apparatus and method of preventing cavities in an ECD copper film
GB0314967D0 (en) * 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
CA2533463A1 (en) * 2003-08-12 2005-02-17 F. Hoffmann-La Roche Ag 2-amino-5-benzoylthiazole npy antagonists
CN100393718C (zh) * 2003-08-12 2008-06-11 霍夫曼-拉罗奇有限公司 作为npy拮抗剂的噻唑衍生物
WO2006110809A2 (en) * 2005-04-12 2006-10-19 Elan Pharma International, Limited Nanoparticulate lipase inhibitor formulations
CA2609634C (en) * 2005-05-03 2011-02-01 F. Hoffmann-La Roche Ag Tetracyclic azapyrazinoindolines as 5-ht2 ligands
KR100910000B1 (ko) * 2005-05-13 2009-07-29 씨제이제일제당 (주) 리파아제 저해제 함유 약학 조성물
JP5044398B2 (ja) * 2005-06-09 2012-10-10 武田薬品工業株式会社 固形製剤
DE602006006712D1 (de) * 2005-08-18 2009-06-18 Hoffmann La Roche Thiazolylpiperidin-derivate nützlich als h3 rezeptor modulatoren
US20070077310A1 (en) * 2005-10-03 2007-04-05 University Of Tennessee Research Foundation Methods of reducing the production of reactive oxygen species and methods of screening or identifying compounds and compositions that reduce the production of reactive oxygen species
ATE507222T1 (de) * 2005-11-30 2011-05-15 Hoffmann La Roche 1,1-dioxo-thiomorpholinyl-indolyl-methanon- derivate zur verwendung als h3-modulatoren
CA2630270A1 (en) * 2005-11-30 2007-06-07 F. Hoffmann-La Roche Ag 5-substituted indole-2-carboxamide derivatives
DE602006020482D1 (de) * 2005-11-30 2011-04-14 Hoffmann La Roche 1,5-substituierte indol-2-yl amidderivative
ES2333672T3 (es) * 2005-12-09 2010-02-25 F. Hoffmann-La Roche Ag Derivados de amida triciclica para tratamiento de obesidad.
CN101326187A (zh) * 2005-12-15 2008-12-17 霍夫曼-拉罗奇有限公司 吡咯并[2,3-c]吡啶衍生物
BRPI0619985A2 (pt) * 2005-12-16 2011-10-25 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas, métodos para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, de obesidade e de diabetes do tipo ii em um ser humano ou animal e usos dos compostos
EP1803714A1 (en) * 2005-12-27 2007-07-04 KRKA, tovarna zdravil, d.d., Novo mesto Process for preparing crystalline forms of orlistat
BRPI0707916A2 (pt) * 2006-01-13 2011-05-17 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas que os compreendem e uso destes compostos
KR101047274B1 (ko) * 2006-01-23 2011-07-06 에프. 호프만-라 로슈 아게 Ｈ3 수용체 활성을 갖는 사이클로헥실 설폰아마이드 유도체
US7432255B2 (en) * 2006-05-16 2008-10-07 Hoffmann-La Roche Inc. 1H-indol-5-yl-piperazin-1-yl-methanone derivatives
EP2032554A1 (en) * 2006-05-30 2009-03-11 F. Hoffmann-Roche AG Piperidinyl pyrimidine derivatives
EP1872777A1 (en) * 2006-06-27 2008-01-02 LEK Pharmaceuticals D.D. Pharmaceutical composition comprising tetrahydrolipstatin
US7514433B2 (en) 2006-08-03 2009-04-07 Hoffmann-La Roche Inc. 1H-indole-6-yl-piperazin-1-yl-methanone derivatives
US20080146559A1 (en) 2006-12-08 2008-06-19 Li Chen 4,5,6,7-Tetrahydro-Thieno [2,3-C] Pyridine Derivatives
TR200607613A2 (tr) * 2006-12-29 2008-07-21 NOBEL İLAÇ SAN.ve TiC.A.Ş. Lipaz inhibitörü içeren farmasötik formülasyonlar
SI2002825T1 (sl) * 2007-06-14 2013-10-30 Krka Farmacevtski sestavki, ki obsegajo orlistat
EA201070378A1 (ru) * 2007-09-17 2010-08-30 Др. Редди`С Лабораторис Лтд. Фармацевтические составы орлистата
WO2009044380A2 (en) 2007-10-05 2009-04-09 Ranbaxy Laboratories Limited Formulations containing orlistat particles having controlled particle size
US20100317642A1 (en) * 2007-10-15 2010-12-16 Inventis Dds Pvt Limited Pharmaceutical composition of orlistat
US8298583B2 (en) 2007-10-19 2012-10-30 Monosol Rx, Llc Film delivery system for tetrahydrolipstatin
US20090220593A1 (en) * 2008-01-29 2009-09-03 Gulati Inder Extended release dosage forms of quetiapine
PL216542B1 (pl) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
US8309107B2 (en) * 2008-10-06 2012-11-13 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
BRPI0901602B8 (pt) * 2009-04-03 2021-05-25 Ems S/A formulação farmacêuticas
MX342962B (es) * 2009-09-18 2016-06-07 Teva Pharmaceuticals Holdings Mexico S A De C V Composicion farmaceutica para bajar de peso y procedimiento para obtener la misma.
UA107369C2 (en) * 2010-02-01 2014-12-25 Lab Bago S A Pharmaceutical composition with anti-obesity activity comprising a premixture of pure orlistat and preparation process
RU2441654C2 (ru) * 2010-02-17 2012-02-10 Лабораториос Баго С.А. Фармацевтическая композиция с активностью против ожирения, включающая премикс чистого орлистата, и способ ее изготовления
US20120039999A1 (en) 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
US20120040008A1 (en) 2010-08-11 2012-02-16 Ashish Chatterji Pharmaceutical compositions of metabotropic glutamate 5 receptor (mglu5) antagonists
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
PL2720723T3 (pl) * 2011-06-15 2018-10-31 Synthon Bv Stabilizowana kompozycja worykonazolu
MX2014000419A (es) 2011-07-15 2014-09-22 Nusirt Sciences Inc Composicones y metodos para modular trayectorias metabolicas.
CN102362863B (zh) * 2011-11-21 2013-06-12 山东新时代药业有限公司 一种含奥利司他的制剂及其制备方法
GB201122213D0 (en) * 2011-12-23 2012-02-01 Norgine Bv Compositions
NL2009995C2 (en) * 2011-12-23 2013-09-18 Norgine Bv Compositions.
WO2013092786A1 (en) 2011-12-23 2013-06-27 Norgine B.V. Compositions comprising cetilistat
US9198454B2 (en) 2012-03-08 2015-12-01 Nusirt Sciences, Inc. Compositions, methods, and kits for regulating energy metabolism
JP2015509976A (ja) * 2012-03-13 2015-04-02 ピラマル エンタープライジーズ リミテッド 代謝障害の治療用薬草組成物
BR112015010947A2 (en) 2012-11-13 2018-06-05 Nusirt Sciences, Inc. compositions and methods for increasing energy metabolism.
DE202012104963U1 (de) 2012-12-19 2013-01-14 Norgine B.V. Cetilistat aufweisende Zusammensetzungen
SG11201507046UA (en) 2013-03-15 2015-10-29 Nusirt Sciences Inc Leucine and nicotinic acid reduces lipid levels
CN104740637A (zh) * 2013-12-31 2015-07-01 北京科信必成医药科技发展有限公司 一种稳定的奥利司他口服制剂及其制备方法
CA2939833A1 (en) 2014-02-27 2015-09-03 Nusirt Sciences, Inc. Compositions and methods for the reduction or prevention of hepatic steatosis
US10743813B2 (en) 2014-09-11 2020-08-18 Rattan Nath Diabetes control using postprandial feedback
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
CN122182527A (zh) 2016-05-05 2026-06-12 阿奎斯蒂弗医疗股份有限公司 增强递送的肾上腺素组合物
US12433850B2 (en) 2016-05-05 2025-10-07 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine and prodrug compositions
US12427121B2 (en) 2016-05-05 2025-09-30 Aquestive Therapeutics, Inc. Enhanced delivery epinephrine compositions
CN108785272B (zh) * 2018-09-04 2019-04-09 中山万汉制药有限公司 一种奥利司他软胶囊及其制备方法
CN115105476B (zh) * 2021-03-23 2023-11-14 山东新时代药业有限公司 一种奥利司他冻干口服制剂及其制备工艺
WO2023076281A1 (en) 2021-10-25 2023-05-04 Aquestive Therapeutics, Inc. Oral and nasal compositions and methods of treatment
CN115300479A (zh) * 2022-08-23 2022-11-08 宁波高新区美诺华医药创新研究院有限公司 奥利司他胶囊制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
JPH04198129A (ja) * 1990-11-28 1992-07-17 Sumitomo Pharmaceut Co Ltd 活性型ビタミンｄ↓３類含有組成物
CA2098167C (en) * 1992-06-24 2006-12-19 Dorothea Isler Foodstuffs and feedstuffs containing a lipase inhibitor
CA2128044C (en) * 1993-08-05 2007-02-20 Klaus-Dieter Bremer Pharmaceutical compositions comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor

Also Published As

Publication number Publication date
CA2258095C (en) 2000-02-22
CN1193752C (zh) 2005-03-23
US6004996A (en) 1999-12-21
CA2258095A1 (en) 1998-08-13
CO4920214A1 (es) 2000-05-29
CN1220600A (zh) 1999-06-23
IL126902A0 (en) 1999-09-22
DK0921796T3 (da) 2001-07-16
HU225035B1 (en) 2006-05-29
EP0921796B1 (en) 2001-03-28
DE69800639T2 (de) 2001-10-31
YU49423B (sh) 2006-01-16
RU2170579C2 (ru) 2001-07-20
AR010704A1 (es) 2000-06-28
MY118371A (en) 2004-10-30
DE69800639D1 (de) 2001-05-03
HK1021313A1 (en) 2000-06-09
CY2264B1 (en) 2003-07-04
WO1998034607A1 (en) 1998-08-13
NO985337D0 (no) 1998-11-16
AU713192B2 (en) 1999-11-25
YU49698A (sh) 1999-09-27
ID26509A (id) 2001-01-11
PT921796E (pt) 2001-09-28
HRP980057B1 (en) 2001-08-31
UY24875A1 (es) 2000-12-29
EP0921796A1 (en) 1999-06-16
SI0921796T1 (en) 2001-06-30
HU0001468D0 (en) 2000-05-28
CZ287154B6 (en) 2000-09-13
NO320445B1 (no) 2005-12-05
GR3036064T3 (en) 2001-09-28
ATE200027T1 (de) 2001-04-15
IL126902A (en) 2002-12-01
NZ332659A (en) 2000-03-27
PE57599A1 (es) 1999-06-11
HUP0001468A3 (en) 2000-12-28
HUP0001468A2 (hu) 2000-09-28
HRP980057A2 (en) 1998-12-31
PL330972A1 (en) 1999-06-21
ES2156028T3 (es) 2001-06-01
CZ352898A3 (cs) 1999-02-17
AU6097298A (en) 1998-08-26
MA24466A1 (fr) 1998-10-01

Similar Documents

Publication Publication Date Title
NO985337D0 (no) Tetrahydrolipstatin-holdige blandinger
ATA93198A (de) Fluoxetinpellets
ATA111897A (de) Kimme
IS5445A (is) Statín-karboxýalkýleter-blöndur
BR9801805A (pt) Dioxacicloalcan-8-ona
NO20002588D0 (no) Bifenylamidinderivater
ATE236897T1 (de) 3-benzylpiperidine
ATA112597A (de) Snowboard - bindung
FI972592A0 (fi) Synkroniseringsfoerfarande
ATA86797A (de) Verschleissschuh
ATA46498A (de) Kunststoffgleitbahn
FI974490A0 (fi) Resontorstruktur
FI970444A0 (fi) Hoensskoetselenhet
FI974270A0 (fi) Abonnentlinjekrets
BR9701194A (pt) Hidrociclo
BR9703453A (pt) Projeto junça
ATE421585T1 (de) Motlinhomologe
DK9700112U3 (da) Brøndramme-brøndlågskombination
FI974390A0 (fi) Baotlyftanordning
FI974280A0 (fi) Luftfoersvarssystem
FI973300A0 (fi) Justerbart armstoed/musunderlag
BR7700737U (pt) Tarraxa
BR9700388A (pt) Fura-fura-areia-aspiral
FI974126A0 (fi) Foensterkonstruktion
BR9700387A (pt) Saca-areia-aspiral

Legal Events

Date Code Title Description
MK1K Patent expired